Matthew L. Kaplan's most recent trade in Nuvectis Pharma Inc was a trade of 11,000 Common Stock done at an average price of $5.8 . Disclosure was reported to the exchange on Nov. 5, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Nuvectis Pharma Inc | Matthew L. Kaplan | Director | Purchase of securities on an exchange or from another person at price $ 5.84 per share. | 05 Nov 2025 | 11,000 | 124,760 | - | 5.8 | 64,240 | Common Stock |
| Nuvectis Pharma Inc | Matthew L. Kaplan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2025 | 30,000 | 113,760 | - | 0 | Common Stock | |
| Nuvectis Pharma Inc | Matthew L. Kaplan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 30,000 | 83,760 | - | 0 | Common Stock | |
| Nuvectis Pharma Inc | Matthew L. Kaplan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2023 | 18,000 | 53,760 | - | 0 | Common Stock | |
| Nuvectis Pharma Inc | Matthew L. Kaplan | Director | Purchase of securities on an exchange or from another person at price $ 17.47 per share. | 12 May 2022 | 1,823 | 35,760 | - | 17.5 | 31,848 | Common Stock |
| Nuvectis Pharma Inc | Matthew L. Kaplan | Director | Purchase of securities on an exchange or from another person at price $ 15.96 per share. | 12 May 2022 | 1,177 | 33,937 | - | 16.0 | 18,785 | Common Stock |
| Nuvectis Pharma Inc | Matthew L. Kaplan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2022 | 15,000 | 15,000 | - | - | Stock Options (right to buy) |